Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Drug Profile

Beclometasone/formoterol/glycopyrrolate - Chiesi Farmaceutici

Alternative Names: BDP/FF/GB; Beclometasone dipropionate/formoterol fumarate/glycopyrrolate bromide; Beclometasone/glycopyrrolate/formoterol; CHF 5993 pMDI; CHF-5993; Riarify; Trimbow

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antiasthmatics; Bronchodilators; Chlorinated steroids; Ethanolamines; Pregnadienetriols; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 22 Feb 2018 CHMP of EMA adopts a positive opinion, recommending the granting of a MAA for beclometasone dipropionate anhydrous/formoterol fumarate dihydrate/glycopyrronium (Riarify) for the maintenance treatment of Chronic obstructive pulmonary disease (by informed consent)
  • 27 Nov 2017 Phase-III clinical trials in Chronic obstructive pulmonary disease in Hungary, Belgium (Inhalation) (NCT03268226) (EudraCT2017-000438-79)
  • 04 Sep 2017 Chiesi Farmaceutici plans a phase III trial for Chronic obstructive pulmonary disease (NCT03268226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top